These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 15230644

  • 1. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.
    Hasler WL, Schoenfeld P.
    Drug Saf; 2004; 27(9):619-31. PubMed ID: 15230644
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW, Clark WK, Moore DJ, Whorwell PJ.
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [Abstract] [Full Text] [Related]

  • 6. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.
    Wagstaff AJ, Frampton JE, Croom KF.
    Drugs; 2003; 63(11):1101-20. PubMed ID: 12749744
    [Abstract] [Full Text] [Related]

  • 7. Safety and tolerability of tegaserod in irritable bowel syndrome management.
    Berardi RR.
    J Am Pharm Assoc (2003); 2004; 44(1):41-51. PubMed ID: 14965152
    [Abstract] [Full Text] [Related]

  • 8. Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review.
    Rivkin A.
    Clin Ther; 2003 Jul; 25(7):1952-74. PubMed ID: 12946544
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
    Appel-Dingemanse S.
    Clin Pharmacokinet; 2002 Jul; 41(13):1021-42. PubMed ID: 12403641
    [Abstract] [Full Text] [Related]

  • 14. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
    Lewis JH.
    Drug Saf; 2011 Jul 01; 34(7):545-65. PubMed ID: 21663331
    [Abstract] [Full Text] [Related]

  • 15. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.
    Fock KM, Wagner A, Asia Pacific Gastroenterology Group.
    J Gastroenterol Hepatol; 2007 Aug 01; 22(8):1190-8. PubMed ID: 17524039
    [Abstract] [Full Text] [Related]

  • 16. Tegaserod for the Treatment of Irritable Bowel Syndrome.
    Madia VN, Messore A, Saccoliti F, Tudino V, De Leo A, De Vita D, Bortolami M, Scipione L, Pindinello I, Costi R, Di Santo R.
    Antiinflamm Antiallergy Agents Med Chem; 2020 Aug 01; 19(4):342-369. PubMed ID: 31518227
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Tegaserod in treatment of women with irritable bowel syndrome].
    Munck LK, Ainsworth MA.
    Ugeskr Laeger; 2007 Jun 04; 169(23):2190-2. PubMed ID: 17592683
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.